SynthesisFrontiers in endocrinology2026
Systematic review of the efficacy and safety of biologically and tissue-derived therapies for the treatment of diabetic foot.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot ulcers are a common and serious complication in diabetic patients, and traditional treatments have limited healing rates. Autologous cells and related products, as an emerging therapy, require systematic evaluation for their efficacy and safety. Objective: To systematically evaluate and meta-analyze the efficacy and safety of autologous cells and related products in the treatment of diabetic foot ulcers. Methods: Relevant randomized controlled trials up to November 2025 were searched in PubMed and Embase databases. Patients with diabetic foot ulcers were included, and the intervention was autologous cell therapy. Data on healing rate, percentage reduction in ulcer area, and healing days were extracted and meta-analyzed using RevMan 5.3. Results: A total of 26 randomized controlled trials (RCTs) involving 2,214 patients were included. The autologous cell therapy group showed a significantly higher rate of complete healing than the control group (RR = 0.54, 95% CI: 0.45). The difference in ulcer area reduction was significantly greater (MD = 24.6%, 95%CI: 18.3-30.9, P<0.001) and healing time was significantly shorter (MD= -48.8 days, 95% CI: -74.19 to -23.48, P = 0.0002). There were no significant differences in adverse events such as amputation and mortality between the two groups. In conclusion, autologous cell therapy can significantly improve the healing rate and accelerate ulcer healing in diabetic foot ulcers, with good safety, making it a promising treatment option. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261293843.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.